Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
用户7r3s6GtS4g7E
1个月前
44
10
已完结
1. 系统已在2025-12-11 09:33:30对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S0140-6736(25)01176-6
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673625011766
其他信息:
出版社: Elsevier BV
作者: Agnes Gasiorek; Arne Heydorn; Sanaz Gabery; Julie B Hjerpsted; Katrine Kirkeby; Thomas Kruse; Signe B Petersen; Søren Toubro; Andreas Vegge; Cassandra Key
